SGLT2 inhibitor

SGLT2 inhibitors or Sodium-glucose co-transporter-2 inhibitors are a class of medications used primarily in the treatment of type 2 diabetes. They work by preventing the kidneys from reabsorbing glucose back into the blood, thereby promoting the excretion of glucose in urine.

Mechanism of Action

SGLT2 inhibitors work by blocking the sodium-glucose co-transporter-2 (SGLT2), which is responsible for the majority of glucose reabsorption by the kidneys. By inhibiting this transporter, these medications increase the amount of glucose excreted in the urine, thereby lowering blood glucose levels.

Uses

SGLT2 inhibitors are primarily used in the treatment of type 2 diabetes. They may also be used in the management of heart failure and chronic kidney disease.

Side Effects

Common side effects of SGLT2 inhibitors include urinary tract infections, yeast infections, and increased urination. Rare but serious side effects may include ketoacidosis and kidney injury.

Examples

Examples of SGLT2 inhibitors include canagliflozin, dapagliflozin, and empagliflozin.

See Also

• Type 2 diabetes
• Heart failure
• Chronic kidney disease
• Medication
• Canagliflozin
• Dapagliflozin
• Empagliflozin

File:WHO Rod.svg This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia